• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Extrapleural pneumonectomy for diffuse, malignant mesothelioma.

作者信息

DaValle M J, Faber L P, Kittle C F, Jensik R J

出版信息

Ann Thorac Surg. 1986 Dec;42(6):612-8. doi: 10.1016/s0003-4975(10)64593-6.

DOI:10.1016/s0003-4975(10)64593-6
PMID:2431665
Abstract

Extrapleural pneumonectomy for malignant mesothelioma is a radical procedure that entails en bloc removal of the parietal pleura, lung, pericardium, and diaphragm. Minimal tumor remains after this procedure; palliation and occasional long-term survival may be achieved in properly selected patients. Extrapleural pneumonectomy for diffuse, malignant mesothelioma was done in 33 patients (27 male and 6 female) with 18 procedures on the left side and 15 on the right. There was a history of exposure to asbestos in 16 (48%) of the patients. Histological classification revealed that 20 tumors were epithelial, 10 were mixed, and 3 were sarcomatous. Good palliation, defined as survival for 24 months with a return to fairly normal activities, was obtained in 8 patients (24%) and survival for 36 months was achieved in 5 patients. Three patients died of the disease at 59 months, 60 months, and 82 months. There were 3 operative deaths (9.1%), and serious postoperative complications occurred in 8 patients (24%). Postoperative adjunctive therapy consisting of chemotherapy or irradiation or both was given to approximately one-half of the patients. These findings indicate that extrapleural pneumonectomy for malignant mesothelioma can be done with an acceptable morbidity and mortality. Palliation is achieved in 24% of patients, and there may be an occasional long-term survivor.

摘要

相似文献

1
Extrapleural pneumonectomy for diffuse, malignant mesothelioma.
Ann Thorac Surg. 1986 Dec;42(6):612-8. doi: 10.1016/s0003-4975(10)64593-6.
2
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.胸膜外全肺切除术在恶性胸膜间皮瘤中的作用。一项肺癌研究组试验。
J Thorac Cardiovasc Surg. 1991 Jul;102(1):1-9.
3
Extrapleural pneumonectomy, chemotherapy, and radiotherapy in the treatment of diffuse malignant pleural mesothelioma.胸膜外肺切除术、化疗及放疗在弥漫性恶性胸膜间皮瘤治疗中的应用
J Thorac Cardiovasc Surg. 1991 Jul;102(1):10-4; discussion 14-5.
4
Malignant pleural mesothelioma: surgical management in 285 patients.恶性胸膜间皮瘤:285例患者的外科治疗
Ann Thorac Surg. 2008 Jan;85(1):257-64; discussion 264. doi: 10.1016/j.athoracsur.2007.06.066.
5
[Extended extrapleural pneumonectomy by median approach for advanced malignant mesothelioma with right supraclavicular lymph node metastasis--a case report].[经正中入路扩大胸膜外全肺切除术治疗伴右锁骨上淋巴结转移的晚期恶性间皮瘤——病例报告]
Nihon Kyobu Geka Gakkai Zasshi. 1994 Mar;42(3):404-8.
6
The Role of Extrapleural Pneumonectomy in Malignant Pleural Mesothelioma.胸膜外全肺切除术在恶性胸膜间皮瘤中的作用
Thorac Surg Clin. 2020 Nov;30(4):461-471. doi: 10.1016/j.thorsurg.2020.08.004. Epub 2020 Sep 12.
7
[Malignant pleural mesothelioma: comparison of radical pleurectomy und extrapleural pneumonectomy].[恶性胸膜间皮瘤:根治性胸膜切除术与胸膜外全肺切除术的比较]
Chirurg. 2013 Jun;84(6):487-91. doi: 10.1007/s00104-012-2432-5.
8
The effect of extent of local resection on patterns of disease progression in malignant pleural mesothelioma.局部切除范围对恶性胸膜间皮瘤疾病进展模式的影响。
Ann Thorac Surg. 2004 Jul;78(1):245-52. doi: 10.1016/j.athoracsur.2004.01.034.
9
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.胸膜外肺切除术与胸膜剥脱术/纤维板剥脱术治疗恶性胸膜间皮瘤的手术疗效:663例患者的结果
J Thorac Cardiovasc Surg. 2008 Mar;135(3):620-6, 626.e1-3. doi: 10.1016/j.jtcvs.2007.10.054. Epub 2008 Feb 14.
10
Extrapleural pneumonectomy or pleurectomy/decortication for malignant pleural mesothelioma.用于恶性胸膜间皮瘤的胸膜外肺切除术或胸膜剥脱术/纤维板剥脱术
Gen Thorac Cardiovasc Surg. 2014 Sep;62(9):516-21. doi: 10.1007/s11748-014-0389-7. Epub 2014 Mar 19.

引用本文的文献

1
Review of malignant pleural mesothelioma survival after talc pleurodesis or surgery.滑石粉胸膜固定术或手术后恶性胸膜间皮瘤生存情况综述。
J Thorac Dis. 2017 Dec;9(12):5423-5433. doi: 10.21037/jtd.2017.11.55.
2
Diffuse malignant pleural mesothelioma: a multi-institutional clinicopathological study.弥漫性恶性胸膜间皮瘤:一项多机构临床病理研究。
Surg Today. 2008;38(11):993-8. doi: 10.1007/s00595-008-3776-9. Epub 2008 Oct 29.
3
Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma. A treatment option in selected cases?
用于弥漫性恶性胸膜间皮瘤的胸膜外全肺切除术。是特定病例的一种治疗选择吗?
Jpn J Thorac Cardiovasc Surg. 2001 Feb;49(2):89-93. doi: 10.1007/BF02912122.
4
Photodynamic therapy as adjuvant therapy in surgically treated pleural malignancies.光动力疗法作为手术治疗胸膜恶性肿瘤的辅助治疗
Br J Cancer. 1997;76(6):819-26. doi: 10.1038/bjc.1997.468.
5
[Problems in diagnosis and therapy of malignant pleural mesothelioma].[恶性胸膜间皮瘤的诊断与治疗问题]
Med Klin (Munich). 1997 Feb 15;92(2):101-5. doi: 10.1007/BF03042291.
6
Diffuse malignant mesothelioma of the pleura: a clinicopathological study of six patients with a prolonged symptom-free interval or extended survival after biopsy and a review of the literature of long-term survival.胸膜弥漫性恶性间皮瘤:6例活检后症状缓解期延长或生存期延长患者的临床病理研究及长期生存文献综述
Virchows Arch A Pathol Anat Histopathol. 1993;422(6):445-51. doi: 10.1007/BF01606452.
7
Cerebral metastases in pleural mesothelioma: case report and review of the literature.胸膜间皮瘤的脑转移:病例报告及文献综述
J Neurooncol. 1993 Jul;17(1):21-6. doi: 10.1007/BF01054270.
8
[Pleural mesothelioma--problems in diagnosis and clinical course in 25 patients].[胸膜间皮瘤——25例患者的诊断问题及临床病程]
Langenbecks Arch Chir. 1989;374(2):105-10. doi: 10.1007/BF01261619.
9
Chemosensitivity and cytokine sensitivity of malignant mesothelioma.
Cancer Chemother Pharmacol. 1991;28(6):420-6. doi: 10.1007/BF00685817.
10
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.异环磷酰胺联合美司钠治疗恶性间皮瘤的扩展II期试验。
Invest New Drugs. 1992 Nov;10(4):337-43. doi: 10.1007/BF00944192.